1. "CTCR Scholars"
Formats
  1. Meeting Abstract (846)
  2. Journal Article (546)
  3. Review (68)
  4. Research Letter (35)
  5. Editorial (29)
  6. Correspondence (24)
  7. Miscellaneous (16)
  8. Book Section (10)
  9. Guidelines (7)
  10. Conference Paper (4)
Groups
  1. CTCR Scholars (1585)
  2. Department of Medicine (1369)
  3. Hematologic Malignancies, Division of (1045)
  4. MSK Grad Students (989)
  5. Master of Science in Clinical and Translational Cancer Research (956)
  6. Center for Hematologic Malignancies (955)

More Groups

People
  1. Sergio Giralt (539)
  2. Miguel-Angel Perales (397)
  3. Michael Scordo (366)
  4. Gunjan Shah (321)
  5. Sean Devlin (321)
  6. Parastoo Dahi (294)

More People

Years
  1. 2025 (68)
  2. 2024 (227)
  3. 2023 (261)
  4. 2022 (230)
  5. 2021 (166)
  6. 2020 (211)

More Years

Publications
  1. Blood (294)
  2. Biology of Blood and Marrow Transplantation (187)
  3. Journal of Clinical Oncology (140)
  4. Annals of Surgical Oncology (81)
  5. Bone Marrow Transplantation (65)
  6. Transplantation and Cellular Therapy (55)

More Publications

Publishers
  1. Elsevier Inc. (390)
  2. American Society of Hematology (345)
  3. American Society of Clinical Oncology (153)
  4. Nature Publishing Group (130)
  5. Springer (98)
  6. American Association for Cancer Research (65)

More Publishers

Results (1585)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Redefining early-onset cancer and risk of hereditary cancer predisposition
    Meeting Abstract

    Stadler, Z. K.; Maio, A.; Khurram, A.; Kemel, Y.; Padunan, A.; Borio, M.; Sheehan, M.; Murciano-Goroff, Y. R.; Walsh, M. F.; Will, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma
    Meeting Abstract

    Mikiver, R.; Olofsson Bagge, R.; Marchetti, M. A.; Van Akkooi, A. C. J.; Coit, D. G.; Ingvar, C.; Isaksson, K.; Scolyer, R. A.; Thompson, J.; Varey, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2 -mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Liu, S. Y.; Jee, J.; Santini, F. C.; Schoenfeld, A. J.; Eichholz, J.; Johnson, K.; Martinez, A.; Guo, J.; Riaz, N.; Lee, N. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant
    Meeting Abstract

    Shah, G. L.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D. J.; Gupta, G. K.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC)
    Meeting Abstract

    Keane, F.; Saadat, L.; O'Connor, C.; Chou, J. F.; Brannon, A. R.; Cowzer, D.; Crowley, F.; Debnath, N.; Bowman, A.; Xu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers
    Meeting Abstract

    Balogun, F.; Altoe, M.; O'Connor, C.; Chowdhury, N.; Cercek, A.; Lee, C. K.; Foote, M. B.; Kim, D.; Maron, S. B.; Kim, D. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions
    Meeting Abstract

    Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save